BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Conclusion BEAM seemed to be associated with higher toxicity with comparable efficacy to HDM ASCT. Longer follow-up is needed to determine whether there is any significant difference in PFS between the 2 groups. Micro-Abstract We report a retrospective study comparing BEAM (BCNU, etoposide, cytarabine, and melphalan) conditioning (n = 24) versus high-dose melphalan (HDM) (n = 19) for patients with myeloma receiving salvage autologous stem cell transplantation (ASCT) whose disease progressed after a first ASCT with HDM. BEAM seemed to be associated with higher toxicity with comparable efficacy to ASCT with HDM. Longer follow-up is needed to determine whether there is any significant difference in progression-free survival (PFS) between the 2 groups.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Legislation | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants